Overview

Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer

Status:
Not yet recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
This clinical trial will evaluate the safety of Cabazitaxel in combination with 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Peter MacCallum Cancer Centre, Australia
Treatments:
177Lu-PSMA-617